Emerging drugs for secondary hyperparathyroidism.

@article{Cozzolino2015EmergingDF,
  title={Emerging drugs for secondary hyperparathyroidism.},
  author={Mario Cozzolino and James R. Tomlinson and Liron Walsh and Antonio Bellasi},
  journal={Expert opinion on emerging drugs},
  year={2015},
  volume={20 2},
  pages={
          197-208
        }
}
INTRODUCTION Secondary hyperparathyroidism (SHPT), a common, serious, and progressive complication of chronic kidney disease (CKD), is characterized by elevated serum parathyroid hormone (PTH), parathyroid gland hyperplasia, and mineral metabolism abnormalities. These disturbances may result in CKD-mineral and bone disorder (CKD-MBD), which is associated with poor quality of life and short life expectancy. AREAS COVERED The goal of SHPT treatment is to maintain PTH, calcium, and phosphorus… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide

  • Therapeutics and clinical risk management
  • 2017
VIEW 5 EXCERPTS
CITES BACKGROUND

Etelcalcetide: First Global Approval

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED